CSIMarket
 


Concert Pharmaceuticals Inc   (CNCE)
Other Ticker:  
 

Concert Pharmaceuticals Inc 's Leverage Ratio

CNCE's quarterly Leverage Ratio and Total Liabilities, Equity growth




CNCE Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change 34.4 % 4.14 % -32.86 % -14.44 % -22.5 %
Y / Y Total Liabilities Change 30.35 % 87.01 % 103.63 % 88.93 % 14.22 %
Leverage Ratio MRQ 0.28 0.38 0.69 0.47 0.29
Overall Ranking # # # # #
Seq. Equity Change 4.29 % 66.9 % -31.77 % 13.17 % -19.19 %
Seq. Total Liabilities Change -22.1 % -8.03 % -0.46 % 82.78 % 11.76 %



Leverage Ratio third quarter 2022 Comment
Due to repayements of liabilities of -22.1% Concert Pharmaceuticals Inc improved Leverage Ratio in third quarter 2022 to 0.28, above company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry Concert Pharmaceuticals Inc achieved lowest Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Leverage Ratio?
Who are CNCE Customers?
Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Concert Pharmaceuticals Inc 's Equity $ 133 Millions Visit CNCE's Balance sheet
Concert Pharmaceuticals Inc 's Total Liabilities $ 38 Millions Visit CNCE's Balance sheet
Source of CNCE's Sales Visit CNCE's Sales by Geography


Cumulative Concert Pharmaceuticals Inc 's Leverage Ratio

CNCE's Leverage Ratio for the trailling 12 Months

CNCE Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth 34.4 % 4.14 % -32.86 % -14.44 % -22.5 %
Y / Y Total Liabilities TTM Growth 30.35 % 87.01 % 103.63 % 88.93 % 14.22 %
Leverage Ratio TTM 0.43 0.44 0.39 0.3 0.23
Total Ranking TTM # 397 # 967 # 640 # 362 # 567
Seq. Equity TTM Growth 4.29 % 66.9 % -31.77 % 13.17 % -19.19 %
Seq. Total Liabilities TTM Growth -22.1 % -8.03 % -0.46 % 82.78 % 11.76 %


TTM Leverage Ratio Comment
On the trailing twelve months basis Due to repayements of liabilities of -22.1% Concert Pharmaceuticals Inc decreased Leverage Ratio in the III. Quarter to 0.43, above Concert Pharmaceuticals Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 107 other companies have achieved lower Leverage Ratio than Concert Pharmaceuticals Inc . While total ranking remained unchanged compare to previous quarter at no. 397.

Explain Leverage Ratio?
Who are CNCE Customers?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 213
Within the Market # 397


TTM Leverage Ratio Statistics
High Average Low
0.44 0.22 0.09
(Jun 30 2022)   (Jun 30 2018)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Equity
Alkermes Plc   0.77 $ 803.314  Millions$ 1,042.854  Millions
Cingulate Inc   0.76 $ 6.390  Millions$ 8.367  Millions
Rani Therapeutics Holdings Inc   0.76 $ 66.008  Millions$ 86.607  Millions
Atreca inc   0.75 $ 72.388  Millions$ 96.253  Millions
Ibio inc   0.75 $ 36.196  Millions$ 48.368  Millions
Verastem Inc   0.74 $ 46.540  Millions$ 62.873  Millions
Ironwood Pharmaceuticals inc   0.72 $ 422.967  Millions$ 591.063  Millions
Yumanity Therapeutics Inc   0.71 $ 3.899  Millions$ 5.476  Millions
Tango Therapeutics Inc   0.70 $ 191.084  Millions$ 273.072  Millions
Bellerophon Therapeutics inc  0.70 $ 5.180  Millions$ 7.428  Millions
Roivant Sciences Ltd   0.70 $ 1,054.933  Millions$ 1,514.149  Millions
Equillium Inc   0.68 $ 19.125  Millions$ 28.160  Millions
Qualigen Therapeutics Inc   0.68 $ 10.808  Millions$ 15.916  Millions
Horizon Therapeutics Public Limited Company  0.68 $ 3,409.754  Millions$ 5,033.687  Millions
Zymeworks Inc   0.67 $ 120.505  Millions$ 179.758  Millions
Oncotelic Therapeutics Inc   0.67 $ 16.050  Millions$ 24.026  Millions
Timber Pharmaceuticals inc   0.66 $ 5.073  Millions$ 7.633  Millions
Frequency Therapeutics Inc   0.66 $ 54.040  Millions$ 81.973  Millions
Revelation Biosciences Inc   0.66 $ 1.463  Millions$ 2.228  Millions
Igm Biosciences Inc   0.65 $ 212.761  Millions$ 328.175  Millions
Eagle Pharmaceuticals inc   0.65 $ 150.133  Millions$ 231.780  Millions
Abvc Biopharma Inc   0.65 $ 3.682  Millions$ 5.693  Millions
Actinium Pharmaceuticals Inc   0.64 $ 45.561  Millions$ 71.255  Millions
Novabay Pharmaceuticals Inc   0.62 $ 8.592  Millions$ 13.784  Millions
Organogenesis Holdings Inc   0.62 $ 157.963  Millions$ 256.328  Millions
Syros Pharmaceuticals Inc   0.61 $ 78.938  Millions$ 129.171  Millions
Vallon Pharmaceuticals Inc   0.61 $ 2.110  Millions$ 3.459  Millions
Nature s Sunshine Products inc   0.61 $ 85.766  Millions$ 141.754  Millions
Alpine Immune Sciences Inc   0.60 $ 109.590  Millions$ 182.009  Millions
Pds Biotechnology Corp  0.59 $ 27.828  Millions$ 47.059  Millions

Date modified: 2022-11-08T16:42:48+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ALTX's Profile

Stock Price

ALTX's Financials

Business Description

Fundamentals

Charts & Quotes

ALTX's News

Suppliers

ALTX's Competitors

Customers & Markets

Economic Indicators

ALTX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071